nsc-366140 and Lung-Neoplasms

More active agents are needed in the treatment of metastatic non-small cell lung cancer. Pyrazoloacridine (PZA) is a 9-methoxy acridine compound containing a reducible 5-nitro substituent. Although the mechanism of action of PZA is unknown, the acridine compounds are known to cause cytotoxicity by interaction with DNA and RNA.. Eighteen patients with metastatic non-small cell lung carcinoma were treated with pyrazoloacridine. Pyrazoloacridine was administered as a three-hour infusion at 750 mg/M2 every 21 days.. There were no objective responses. One patient maintained stable disease for 20 months. Median survival was 4.8 months. The primary toxicity was granulocytopenia with 5 patients experiencing severe infections.. Pyrazoloacridine has no demonstrable activity in patients with metastatic non-small cell carcinoma of the lung when given at this dose and schedule.

Topics: Acridines; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazoles; Survival Analysis

Topics: Acridines; Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Evaluation; Humans; Kidney Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Pyrazoles; Thrombocytopenia; Vomiting